Calamos Wealth Management LLC increased its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 21.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 84,030 shares of the company's stock after buying an additional 14,568 shares during the quarter. Calamos Wealth Management LLC's holdings in Zoetis were worth $13,691,000 at the end of the most recent quarter.
A number of other large investors have also bought and sold shares of ZTS. Darwin Wealth Management LLC bought a new position in Zoetis in the 3rd quarter worth $31,000. First Personal Financial Services acquired a new stake in Zoetis during the third quarter worth about $33,000. Capital Performance Advisors LLP purchased a new position in shares of Zoetis in the 3rd quarter valued at about $33,000. Dunhill Financial LLC grew its holdings in shares of Zoetis by 80.6% during the third quarter. Dunhill Financial LLC now owns 168 shares of the company's stock worth $33,000 after buying an additional 75 shares during the last quarter. Finally, Quarry LP grew its stake in Zoetis by 273.2% in the 2nd quarter. Quarry LP now owns 209 shares of the company's stock valued at $36,000 after acquiring an additional 153 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.
Shares of ZTS opened at $171.93 on Tuesday. The stock has a market capitalization of $77.57 billion, a price-to-earnings ratio of 32.32, a PEG ratio of 2.72 and a beta of 0.90. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $200.53. The firm has a fifty day simple moving average of $169.62 and a 200 day simple moving average of $179.44.
Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, beating analysts' consensus estimates of $1.46 by $0.12. The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The business's quarterly revenue was up 11.6% compared to the same quarter last year. During the same period last year, the firm earned $1.36 earnings per share. Research analysts forecast that Zoetis Inc. will post 5.9 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, January 21st will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.16%. This is an increase from Zoetis's previous quarterly dividend of $0.43. The ex-dividend date is Tuesday, January 21st. Zoetis's dividend payout ratio (DPR) is presently 37.59%.
Several equities analysts recently issued reports on ZTS shares. UBS Group began coverage on Zoetis in a research note on Monday, December 9th. They set a "neutral" rating and a $196.00 price objective on the stock. Stifel Nicolaus cut their price objective on shares of Zoetis from $210.00 to $180.00 and set a "buy" rating on the stock in a report on Tuesday, January 7th. JPMorgan Chase & Co. boosted their target price on Zoetis from $225.00 to $230.00 and gave the stock an "overweight" rating in a report on Friday, October 11th. Morgan Stanley decreased their price target on shares of Zoetis from $248.00 to $243.00 and set an "overweight" rating for the company in a research report on Wednesday, January 29th. Finally, Leerink Partners started coverage on shares of Zoetis in a research report on Monday, December 2nd. They issued an "outperform" rating and a $215.00 price objective for the company. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $215.00.
Get Our Latest Analysis on Zoetis
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Zoetis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zoetis wasn't on the list.
While Zoetis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.